More articles at source.
Columbia University Physics Professor Michael Tuts speaks to the audience Thursday 27 April 2017 and time 19:30 at the Eugenides Foundation Amphitheater.   At the invitation of the Columbia University alumni association in Greece, professor Michael Tuts will give a single talk with a central axis three questions:   -Why are we interested in the Higgs boson?; -How they discovered it 6.000 scientists at CERN; -What is the next step;   Professor Michael Tuts' research focuses on High Energy Experimental Physics.   He headed the US research team that participates in the ATLAS experiment, one of the 4 main experiments implemented at the Large Hadron Collider (LHC) at CERN.   In addition to theoretical research, Michael Tuts reaches out to the general public and explains abstract and difficult scientific concepts in an understandable way.   This will be followed by the screening of the digital show: "Phantom of the Universe" in the New Digital Planetarium. There will be two performances (by Dimitra Papanastassopoulou is published by Dioptra Publications 20:45 and 21:30).   From the 'speed race' of protons at the world's largest particle accelerator at CERN to the Big Bang and the 'emerging' Universe, but also the descent to’ a basement in South Dakota, almost 1.500 m below the Earth's surface, the show will introduce viewers to the multifaceted research on dark matter.   Entry to the event is free.

More articles at source.
The US Food and Drug Administration. recently approved the ocrelizumab monoclonal antibody, which received wide indication both for the recurring as well as for her primary progressive form of multiple sclerosis, which constitute the majority of cases of the disease at diagnosis. The primarily developing form, characterized by continuous progression of the patient's disability from the onset of the disease, without distinct relapses or periods of remission and represents the 15% of cases.   Until today no treatment for primary progressive multiple sclerosis had been approved in the US, while also despite the available treatments there are patients with relapsing forms of multiple sclerosis, who continue to show disease activity and progression of their disability.   Ocrelizumab is a monoclonal antibody, which is designed to selectively target a specific type of immune system cell, called CD20- B-lymphocytes, which are thought to contribute to the destruction of myelin (ουσίας που παίζει βασικό ρόλο στη μόνωση και υποστήριξη των νευρικών κυττάρων) και στην αξονική βλάβη (στα νευρικά κύτταρα). This destruction of nerve cells can lead to disability in people with multiple sclerosis. Based on preclinical studies, ocrelizumab binds to CD20 cell surface proteins, expressed on some B cells, but not in stem cells or plasma cells, and therefore important functions of the immune system can be preserved. Ocrelizumab will be given to patients intravenously every 6 months (twice a year) and will be able to change the course of the disease for people with multiple sclerosis.   The marketing authorization application for ocrelizumab has also been validated by the European Medicines Agency and is currently under review.

More articles at source.
There's a sea blue that looks only possible through Photoshop or an Instagram filter, but which is true around the islands of the Dodecanese'. He made this observation, and signs it, with all the weight of her own opinion, the well-known correspondent of the newspaper 'Guardian', Hannah Jane Parkinson, on her trek to the islands of the Southeast Aegean, which was published on 23 April.   In her extensive reporting, the British correspondent sings the praises of the islands of the region and even the smaller ones, like Kalymnos, Leros, Telendos and Lipsi, who enchanted her with the unpretentious simplicity and unparalleled beauty of unpopular tourist destinations.   Listing one by one the attractions of these islands, offering detailed access details’ these, Parkinson's makes an indirect one, but eloquent in praise and admiration, advertisement for the beauty of those places. She declares herself 'enchanted'’ of everything, but she expresses her special preference for Leros and its contrasts (where) architecture and history are deliciously intertwined', as he emphatically emphasizes.   The same correspondent expresses herself in a reassuring manner to her readers regarding any fears that may arise from the refugee situation, stressing that most islands were little or not affected by the crisis.

More articles at source.

Kostas Fouzas (kf@newsauto.gr)   Via Twitter Elon Musk, CEO of Tesla, brings back to the fore the company's plans for its first pick-up model. Especially, confirmed that the said project will come to fruition and thus the production model will be released in the 2019 in the American market initially (where this particular category of vehicles records high sales figures). On a technical level now, we expect a fully electric pick-up, with four-wheel drive, great horsepower (0-100 km/h σε 6 sec approx) and autonomy that will reach 500 km.   From the electronically edited spy photos that have been published on the internet from time to time, like the one we present to you, it looks like the production model will retain Tesla's design identity up front, it will have a double-cab body and a large cargo area. In fact, sources from Tesla claim that their model will not lag behind in anything compared to the traditional players in the category.   End, note that the first Tesla pick-up will have all the technological elements with which the company equips its models (among them an autonomous driving system).